source
- Viatris to acquire Pacira BioSciences for $1.65 billion to expand non‑opioid pain portfolioViatris announced a $1.65 billion acquisition of Pacira BioSciences, aiming to broaden its non‑opioid pain‑relief offerings. The deal includes Pacira's marketed products Exparel and Zilretta, which…
- Aspen Neuroscience and Bambusa Therapeutics announce plans to go public amid biotech IPO surgeAspen Neuroscience, a cell therapy company backed by Gilead, and Bambusa Therapeutics, an I&I biotech founded by former BioNTech scientists, have each filed paperwork to launch initial public offer…